Treatment of Elderly Patients with Overactive Bladder: Has Mirabegron Come of Age? (European Urology)

The introduction of ?3-adrenergic receptor (B3-AR) agonists has broadened the treatment spectrum for patients with overactive bladder syndrome (OAB). The clinical efficacy is comparable to muscarinic receptor antagonists (MRAs) with the advantage of fewer cholinergic side effects [1]. These side effects, especially dry mouth and constipation, occur frequently and are often the reason for treatment discontinuation. Moreover, MRAs can have interactions with other anticholinergic drugs (eg, antidepressants, antiemetics, antihistamines), also known as the anticholinergic burden.